Capio Biosciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Capio Biosciences is a private, pre-revenue diagnostics company founded in 2019 and headquartered in Cambridge, Massachusetts, USA. The company is developing the CapioCyte platform, which utilizes a novel combination of biomimetic cell rolling and adhesion to achieve significantly greater sensitivity (reportedly 10-100x) in capturing CTCs compared to existing technologies. While still in the research and development stage, early clinical data is promising, positioning CapioCyte as a potential future tool for cancer research and clinical diagnostics. The company has secured non-dilutive grant funding and established a subsidiary in Korea.

Oncology

Technology Platform

CapioCyte CTC System: An ultra-sensitive platform for capturing and analyzing Circulating Tumor Cells (CTCs) from whole blood using a novel combination of biomimetic cell rolling and adhesion.

Opportunities

The growing liquid biopsy market, driven by demand for non-invasive cancer monitoring, presents a significant opportunity.

Capio's claimed 10-100x sensitivity advantage could position it as a best-in-class research tool and, eventually, a clinical diagnostic for early detection, therapy selection, and recurrence monitoring in oncology.

Risk Factors

Key risks include failure to validate its high-sensitivity claims in larger clinical studies, intense competition from established liquid biopsy companies, and the challenge of securing sufficient funding to navigate the costly regulatory and commercialization pathway for a new diagnostic device.

Competitive Landscape

Capio competes in the crowded liquid biopsy space, facing large players like Guardant Health (cfDNA) and Menarini Silicon Biosystems (CellSearch CTC system). Its differentiation is based on superior CTC capture sensitivity, but it must overcome the market dominance, clinical validation, and commercial scale of these incumbents.

More companies in Diagnostics & Precision Medicine →More companies in United States →